• 咨询热线
    客服服务热线 13671568941/15317326293
  • 在线咨询
  • 微信客服
    微信客服
  • 公众号
    扫码关注公众号

VGX-1027

CAS No. 6501-72-0

VGX-1027 ( VGX-1027 )

产品货号. M15470 CAS No. 6501-72-0

VGX-1027(GIT27) 是一种异恶唑化合物,具有多种免疫调节特性;减少纯化的小鼠巨噬细胞分泌 IL-1β、TNF-α 和 IL-10。

纯度: >98% (HPLC)

COA Datasheet HNMR HPLC MSDS Handing Instructions
规格 价格/人民币 库存 数量
5MG ¥425 有现货
10MG ¥617 有现货
25MG ¥1190 有现货
50MG ¥2130 有现货
100MG ¥3321 有现货
500MG 获取报价 有现货
1G 获取报价 有现货
1 mL x 10 mM in DMSO ¥416 有现货

生物学信息

  • 产品名称
    VGX-1027
  • 注意事项
    本公司产品仅用于科研实验,不得用于人体或动物的临床与诊断
  • 产品简述
    VGX-1027(GIT27) 是一种异恶唑化合物,具有多种免疫调节特性;减少纯化的小鼠巨噬细胞分泌 IL-1β、TNF-α 和 IL-10。
  • 产品描述
    VGX-1027(GIT27) is an isoxazole compound that exhibits various immunomodulatory properties; reduce the secretion of IL-1beta, TNF-alpha and IL-10 from purified murine macrophages.(In Vitro):VGX-1027 (37.5, 75, 150, 300 μM; for 24 h) does not affect the viability of tumor cells,including the three malignant rodent cell lines (mouse fibrosarcoma L929, rat astrocytoma C6, and mouse melanoma B16) and the four human cell lines (adenocarcinoma HeLa, breast carcinoma BT20, colon carcinoma LS174, and glioblastoma U251).(In Vivo):VGX-1027 (10, 20 mg/kg of i.p. for 12 day or 100 mg/kg of p.o. for 11 day) successfully counteractes the development of destructive insulitis and hyperglycemia.VGX-1027 (25?mg/kg; ip; single dose) counteracts the uveitis-inducing effect of LPS in eight-week-old male Lewis rats (180-220?g).
  • 体外实验
    VGX-1027 (37.5, 75, 150, 300 μM; for 24 h) does not affect the viability of tumor cells,including the three malignant rodent cell lines (mouse fibrosarcoma L929, rat astrocytoma C6, and mouse melanoma B16) and the four human cell lines (adenocarcinoma HeLa, breast carcinoma BT20, colon carcinoma LS174, and glioblastoma U251).
  • 体内实验
    VGX-1027 (10, 20 mg/kg of i.p. for 12 day or 100 mg/kg of p.o. for 11 day) successfully counteractes the development of destructive insulitis and hyperglycemia. VGX-1027 (25?mg/kg; ip; single dose) counteracts the uveitis-inducing effect of LPS in eight-week-old male Lewis rats (180-220?g). Animal Model:Adult male mice, at 6 to 8 weeks of age with 25 to 30 g Dosage:10, 20 mg/kg for i.p. or 100 mg/kg for p.o.Administration:IP daily for 12 consecutive day or PO daily for 11 consecutive day Result:Successfully counteracted the development of destructive insulitis and hyperglycemia to the mice made diabetic with multiple low doses of Streptozotocin.
  • 同义词
    VGX-1027
  • 通路
    Apoptosis
  • 靶点
    IL Receptor
  • 受体
    IL-10| IL-1β| TNF-α
  • 研究领域
    Inflammation/Immunology
  • 适应症
    ——

化学信息

  • CAS Number
    6501-72-0
  • 分子量
    205.21
  • 分子式
    C11H11NO3
  • 纯度
    >98% (HPLC)
  • 溶解度
    Ethanol: 41 mg/mL (199.79 mM); DMSO: 41 mg/mL (199.79 mM)
  • SMILES
    O=C(O)CC1CC(C2=CC=CC=C2)=NO1
  • 化学全称
    2-(3-phenyl-4,5-dihydroisoxazol-5-yl)acetic acid

运输与储存

  • 储存条件
    (-20℃)
  • 运输条件
    With Ice Pack
  • 稳定性
    ≥ 2 years

参考文献

1.Stosic-Grujicic S, et al. J Pharmacol Exp Ther. 2007, 320(3), 1038-1049.
产品手册
关联产品
  • Benralizumab

    Benralizumab (MEDI-563) (MEDI-563 (anti-IL5RA ); BIW-8405 (anti-IL5RA )) 是一种白介素 5 受体 α(IL-5Rα) 定向的溶细胞单克隆抗体,通过增强抗体依赖性细胞介导的细胞毒性诱导嗜酸性粒细胞直接,快速和几乎完全耗尽。Benralizumab 可用于严重的嗜酸性哮喘研究。

  • Secukinumab

    Secukinumab 是一种完全人源化的单克隆抗 IL-17A 抗体,也是同类产品中第一个获得美国食品和药物管理局批准用于治疗中度至重度斑块状银屑病的抗体。

  • Ixekizumab

    Ixekizumab 是一种人源化 IgG4 单克隆抗体,可选择性结合和中和白细胞介素 IL-17A (KD<3 pM)。Ixekizumab 直接阻断IL-17A与IL-17RA的结合,但不与其他IL-17家族成员结合。Ixekizumab 用于中重度斑块型银屑病的研究。